Sex differences in immune response, neuroinflammation, and hormonal regulation contribute to these disparities, with recent data showing that microglial activation mediates amyloid-to-tau pathology more strongly in females, potentially accelerating disease progression and symptom burden in women with AD [77,78]. This evidence concerns the gene MAPT and Alzheimer disease.